FOLLISTIM Drug Profile
✉ Email this page to a colleague
Summary for Tradename: FOLLISTIM
| Patents: | 4 |
| Applicants: | 1 |
| BLAs: | 3 |
| Drug Prices: | Drug price information for FOLLISTIM |
| Recent Clinical Trials: | See clinical trials for FOLLISTIM |
Recent Clinical Trials for FOLLISTIM
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Ferring Pharmaceuticals | Phase 2 |
| Center for Human Reproduction | Phase 1/Phase 2 |
| Michigan Reproductive Medicine | Phase 4 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for FOLLISTIM Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for FOLLISTIM Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM AQ | follitropin beta | Injection | 021273 | See Plans and Pricing | 2017-01-15 | Company disclosures |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | See Plans and Pricing | 2015-06-16 | Company disclosures |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | See Plans and Pricing | 2017-01-15 | Company disclosures |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | See Plans and Pricing | 2018-07-23 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for FOLLISTIM Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | See Plans and Pricing | 2033-03-11 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | See Plans and Pricing | 2024-12-29 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | See Plans and Pricing | 2029-05-13 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | See Plans and Pricing | 2029-01-29 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for FOLLISTIM
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 463586 | See Plans and Pricing |
| Austria | 87317 | See Plans and Pricing |
| Denmark | 171601 | See Plans and Pricing |
| Luxembourg | 90806 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for FOLLISTIM
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| SPC/GB01/030 | United Kingdom | See Plans and Pricing | PRODUCT NAME: RECOMBINANT CHORIOGONADOTROPIN ALFA; REGISTERED: UK EU/1/00/165/001-006 20010202 |
| SZ 6/2010 | Austria | See Plans and Pricing | PRODUCT NAME: CORIFOLLITROPIN ALFA |
| SZ 13/2001 | Austria | See Plans and Pricing | PRODUCT NAME: LUTROPIN ALFA |
| SZ 17/2001 | Austria | See Plans and Pricing | PRODUCT NAME: CHORIOGONADOTROPHIN ALFA |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
